"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","Bias.arising.from.the.randomization.process.judgement","Bias.arising.from.the.randomization.process.support","Bias.due.to.deviations.from.intended.interventions.judgement","Bias.due.to.deviations.from.intended.interventions.support","Bias.due.to.missing.outcome.data.judgement","Bias.due.to.missing.outcome.data.support","Bias.in.measurement.of.the.outcome.judgement","Bias.in.measurement.of.the.outcome.support","Bias.in.selection.of.the.reported.result.judgement","Bias.in.selection.of.the.reported.result.support","Overall.bias.judgement","Overall.bias.support","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
1,10,"Severe bleeding - WHO/CTCAE grade ≥ 3 or equivalent (0 to 3 months)",NA,"SUBGROUP_AND_OVERALL","Byun 2023 (D)",2022,0,0,0,0,0,14,0,0,1,18,0,0,9.645021,0.422222,0.018492,9.640496,"Byun 2023 was a single study which utilised a factorial 2 x 2 design where double- and single-unit interventions were used with a restrictive or liberal transfusion strategy. (D) indicates double-unit transfusion arms and (S) indicates single-unit transfusion arms.","Low risk","<p>Used a web-based tool (http://bri.snuh.org/pub/_/singlecont/view.do). The exact link expired with the completion of trial, but a group of statisticians designed the randomization model upon request. Despite only including participants' initial randomization and exclusion of participants who withdrew consent as well as late exclusions due to inapproprate inclusion from identification of exclusion criteria post randomization, no significant differences were identified which would suggest issues with randomization</p>","Some concerns","<p>In case patients became hemodynamically unstable due to major bleeding, severe infection, ischemic heart disease, stroke or any other compromising conditions, liberal RBC transfusion was allowed regardless of the grouping to ensure the patients’ safety. Evidence from patient level data that for both groups, multiple transfusions were given as a single unit rather than two units while the reason for deviation was not recorded / reported. The trial protocol was not published / available. Information from authors indicated that transfusion was not given for every hemoglobin measured. Unclear if not administered / administered above or below threshold due to trial context or alternative indication. Lack of information regarding compliance based on hemoglobin count where deviations have the potential to impact transfusion and outcome.</p>","Low risk","<p>Bleeding is reported and analyzed as ITT, with patient level data, no participants were excluded that had bleeding which would result in missing episodes, while major bleeding is significant enough that attention would have likely been brought to the attention of a healthcare provider and documented / assessed.&nbsp;</p>","Low risk","<p>International Society for Thrombosis and Hemostasis criteria for bleeding stated to have been used in methods for determining severity bleeds, although unclear if independent adjudication used with no protocol to explain how investigators went about evaluating bleeding using criteria. Measurement and ascertainment was unlikely to have differed between groups or influenced due to lack of blinding.</p>","Some concerns","<p>Trial not prospectively registered. No pre-published protocol / analysis plan, but major bleeding reported in methods and registry as being planned outcome</p>","Some concerns","<p>The outcome was judged to have some concern for bias in one or more domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011305.pub3/full","10.1002/14651858.CD011305.pub3","10::overall","CD011305_pub3_data","direction_only",FALSE,FALSE,FALSE,0.00272529222196641,-0.00211768333568689,-1.01646249473177,1.02191307917571,-0.0270250551117067,0.0227896884403329,TRUE,FALSE
1,10,"Severe bleeding - WHO/CTCAE grade ≥ 3 or equivalent (0 to 3 months)",NA,"SUBGROUP_AND_OVERALL","Byun 2023 (S)",NA,0,0,0,0,1,15,0,0,1,16,0,0,13.132876,1.066667,0.073075,15.570002,"See (1)","Low risk","<p>Used a web-based tool (http://bri.snuh.org/pub/_/singlecont/view.do) although the exact link expired with the completion of trial, but a group of statisticians designed the randomization model upon request. As a result of only including participants' initial randomization and exclusion of participants who withdrew consent as well as late exclusions post randomization due to inapproprate inclusion, imbalances were identified which resulted in differences in number of participants who were undergoing induction that were allocated to the liberal group as well as the median age in the liberal group being relatively lower. Based on baseline characteristics of all randomized participants, there did not appear to be any imbalances which would indicate issue with randomization.&nbsp;</p>","Some concerns","<p>In case patients became hemodynamically unstable due to major bleeding, severe infection, ischemic heart disease, stroke or any other compromising conditions, liberal RBC transfusion was allowed regardless of the grouping to ensure the patients’ safety. The trial protocol was not published / available. Information from authors indicated that transfusion was not given for every haemoglobin measured. Unclear if not administered / administered above or below threshold due to trial context or alternative indication. Lack of information regarding compliance based on haemoglobin count where deviations have the potential to impact transfusion and outcome.</p>","Low risk","<p>Bleeding is reported and analyzed as ITT, with patient level data, no participants were excluded that had bleeding which would result in missing episodes, while major bleeding is significant enough that attention would have likely been brought to the attention of a healthcare provider and documented / assessed.&nbsp;</p>","Low risk","<p>International Society for Thrombosis and Hemostasis criteria for bleeding stated to have been used in methods for determining severity bleeds, although unclear if independent adjudication used with no protocol to explain how investigators went about evaluating bleeding using criteria. Measurement and ascertainment was unlikely to have differed between groups or influenced due to lack of blinding.</p>","Some concerns","<p>Trial not prospectively registered. No pre-published protocol / analysis plan, but major bleeding reported in methods and registry as being planned outcome</p>","Some concerns","<p>The outcome was judged to have some concern for bias in one or more domain</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011305.pub3/full","10.1002/14651858.CD011305.pub3","10::overall","CD011305_pub3_data","direction_only",FALSE,FALSE,FALSE,0.00272529222196641,-0.00211768333568689,-1.01646249473177,1.02191307917571,-0.0270250551117067,0.0227896884403329,TRUE,FALSE
1,10,"Severe bleeding - WHO/CTCAE grade ≥ 3 or equivalent (0 to 3 months)",NA,"SUBGROUP_AND_OVERALL","De Zern 2016",NA,0,0,0,0,5,59,0,0,2,30,0,0,37.815546,1.271186,0.261877,6.170505,"","Low risk","<p>""The random-number sequence was generated using computer software (JMP Version 9.0, SAS Institute). Treatment assignment was done with a 2:1 ratio, for the LOW:HIGH Hb trigger groups, respectively. Blocking was used to specify a 2:1 ratio of treatment groups for each group of 18 consecutive patients. Sealed opaque sequentially numbered envelopes were opened upon determination of inclusion for each patient in the trial. The randomization sequence and creation and numbering of the envelopes was performed by an investigator who did not enroll or consent patients for the trial.""</p>","Low risk","<p>""The study, by its nature, was not blinded and both the patients and their providers were aware of the treatment assignment groups""</p><p>""There were two protocol deviations, one per arm, where patients were transfused before having reached their preset trigger accidentally. ""</p><p>Given the relatively neglible number of deviations, there is a low likelihood that there was bias due to deviations from intended interventions</p>","Low risk","<p>""Evaluability was 100% in the HIGH arm and 98% (95% CI, 91.06%-99.96%) in the LOW arm. oth patient and clinician deci- sions to withdraw from study were slightly higher in the LOW arm: patient decision two of 59 (3.4%; 95% CI, 0.41%-11.71%) versus zero of 30 (0%; 95% CI, NA-11.57%), and clinician decision five of 59 (8.5%; 95% CI, 2.81%- 18.68%) versus one of 30 (3.3%; 95% CI, 0.08%-17.22%). The two patient reasons for withdrawal of consent were both noted as decreased performance status or fatigue that they believed would improve after transfusion to a higher Hb. Upon subsequent query, both patients believed that they did feel better off the trial. The clinician withdrawals of consent were an inpatient fall attributed to anemia resulting in a head laceration (one patient), sepsis and goal of improved perfusion with higher Hb (two patients), inability to follow trial trigger due to extensive alloantibodies and the requirement to transfusion only when blood was available (one patient), and a decreased patient performance status or fatigue perceived by the provider as related to anemia (one patient). ""</p><p>No reporting of evidence that the result was not biased by missing outcome data through (1) analysis methods that correct for bias; or (2) sensitivity analyses&nbsp;</p><p>No deaths were attributed to the study procedures or severe morbidity as a result of bleeding but were instead attributed to induction mortality related to underlying disease or complication of chemotherapy that was previously known.&nbsp;</p>","Low risk","<p>""Bleeding was graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The patients were assessed for bleeding daily by the treating providers and documented in the daily progress notes. This was prospectively planned at the start of the trial and is the standard protocol for these patients at the institution. The bedside nurses as well as the physicians are required to document bleeding and fatigue daily. There were no adjudicators.""</p><p>Severe bleeding is less subjective and more objective and unlikely to have been influenced by knowledge of the intervention arm</p>","Low risk","<p>No available pre-published analysis plan</p><p>Trial registry reported ""Bleeding [ Time Frame: 60 days ] Number of grade 3-4 bleeding events as defined by CTCAE 4.0"" as a planned outcome but reported and analyzed all bleeding events in the published paper.&nbsp;</p><p>""Bleeding was graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.""</p><p>""Safety outcomes and transfusion variables were compared between study arms with either the Wilcoxon-Mann-Whitney test for continuous factors or the chi-square or Fisher’s exact tests for categorical variables.""</p>","Low risk","<p>The outcome was judged to have low concern for bias in in all domains</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011305.pub3/full","10.1002/14651858.CD011305.pub3","10::overall","CD011305_pub3_data","direction_only",FALSE,FALSE,FALSE,0.00272529222196641,-0.00211768333568689,-1.01646249473177,1.02191307917571,-0.0270250551117067,0.0227896884403329,TRUE,FALSE
1,10,"Severe bleeding - WHO/CTCAE grade ≥ 3 or equivalent (0 to 3 months)",NA,"SUBGROUP_AND_OVERALL","Tay 2020",2020,0,0.858266813955521,0,0,2,149,0,0,3,150,0,0.73662192393736,29.964345,0.671141,0.113773,3.959027,"","Low risk","<p>“We used a secure online electronic randomization platform, and patients were randomly assigned by using a computer-generated randomization sequence. Simple randomization in a 1:1 ratio was based on variable permutated block sizes and was stratified by transplantation center and by type of HCT. The randomization sequence was determined by the Ottawa Hospital Research Institute-Methods Centre statistician, independent from the study. After screening the patient for eligibility and obtaining informed consent, the study nurse randomized the patient using the number in the next chronological order from the randomization lists provided ahead of time by the Methods Centre. This randomization list was secured within a password protected SQL server. The participant’s assignment was only known once all the inclusion criteria were reviewed and&nbsp;“checked-off”&nbsp;online. The local research coordinator/nurse then identifed the transfusion intervention assignment of the participant to the HSCT team.”</p><p>""The baseline patient and disease characteristics were similar in the two randomly assigned groups&nbsp;""</p>","Low risk","<p>""This is an open labeled study. It will be impossible to blind the assigned red cell transfusion trigger to participants and bedside caregivers since the standard of care requires daily knowledge of hemoglobin concentration as part of the participants’ overall HSCT care and safety. There will be no specific measures to blind research coordinators and study statisticians.""</p><p>""Transfusion of RBCs outside the strategy was permitted whenever the treating physician judged it to be clinically indicated, such as in patients with symptomatic anemia. Likewise, transfusions could be withheld for clinical reasons such as blood volume overload.""&nbsp;</p><p>""In the restrictive-strategy group, there were 76 instances (1.64% of all recorded Hb values) in which RBC transfusion occurred above the assigned trigger and 18 instances (0.39% of all recorded Hb values) in which RBC transfusion did not occur. In contrast, there were 13 instances (0.26% of all recorded Hb values) and 235 instances (4.65% of all recorded Hb values) in the liberal strategy group.""&nbsp;</p><p>Deviations not believed to occur in the context of the trial and occurred relatively infrequently, with overall 95% compliance and deviations to occur due to clinical indications which would similarly occur outside the context of the trial.&nbsp;</p><p>The number of severe bleeding events was relatively low and therefore it is unlikely that small relative overall number of deviations were likely to have affected the outcome.&nbsp;</p><p>Intention-to-treat analysis used for analysis&nbsp;</p>","Some concerns","<p>At least one of three bleeding outcome assessments were not completed in 33 and 36 participants in the restrictive and liberal transfusion arms. 4 participants from restrictive were missing all bleeding assessments, 2 participants from liberal were missing all bleeding assessments. Overall, 33 in restrictive and 36 participants in liberal missed at least 1 bleeding assessment.&nbsp;</p><p>No sensitivity analysis was completed evaluating whether outcome was biased by missing data&nbsp;</p><p>Severe morbidity would likely have resulted in participant discontinuation from study, which was not reported to be reason for withdrawal. Additionally, no causes of death were secondary to bleeding.&nbsp;</p>","Low risk","<p>""The WHO Scale is a credible, standardized and validated scale to assess bleeding. Bleeding will be recorded in the data collection forms.""</p><p>""Research Coordinators at each site will complete the case report forms, check them for accuracy and completeness by reviewing source documents and by regular interaction with the transplant team"".&nbsp;</p><p>Bleeding assessments occurred at the time of transplant assessments days 14, 28 and 100. Bleeds were not independently adjudicated. There is more subjectivity in the lower grades which would allow for more undue influence in decisions. For severe bleeding, there is less subjectivity as the severity requires interventions.&nbsp;</p>","Low risk","<p>No pre-specified analysis plan reported for analysis of outcomes in the trial. Pilot trial protocol published prior to final publication with plan to collect bleeding incidence assessed on Day 14, 28 and 100 as per WHO validated bleeding scale with plan for findings from pilot trial to be used for guidance of trial protocol. Trial registry reports plan for collection of WHO Grade 3 or 4 bleeding in first 100 days.</p><p>WHO is a validated scoring scale for bleeding assessments. All grades of bleeding events reported rather than selectively Grade 3 and 4. Individual bleeding assessment results provided by authors outside of publication.</p><p>Analyzed as difference in bleeding events in trial. Description of analysis completed ""Between-group differences in binary outcomes were summarized by using relative risk with 95% CIs and were tested by using x2 or Fisher’s tests, as appropriate. Continuous outcomes were tested with t tests and summarized as mean differences with 95% CIs."" does not suggest bias. No analysis reported for difference in number of participants as information provided by authors outside of trial.</p><p>Through information used from pilot trial protocol in addition to information being provided from authors outside of published trial, there is not believed to be concern for bias for the domain.&nbsp;</p>","Some concerns","<p>The outcome was judged to have some concern for bias in domain 3</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011305.pub3/full","10.1002/14651858.CD011305.pub3","10::overall","CD011305_pub3_data","direction_only",FALSE,FALSE,FALSE,0.00272529222196641,-0.00211768333568689,-1.01646249473177,1.02191307917571,-0.0270250551117067,0.0227896884403329,TRUE,FALSE
1,10,"Severe bleeding - WHO/CTCAE grade ≥ 3 or equivalent (0 to 3 months)",NA,"SUBGROUP_AND_OVERALL","Webert 2008",2008,0,0,0,0,1,29,0,0,0,31,0,0,9.442212,3.2,0.135544,75.547658,"","Low risk","<p>""A computer-generated random treatment allocation schedule was developed with a variable blocking factor with the size of the blocks selected in a random fashion from a limited number of possibilities and was concealed from all study participants. Based on this schedule, patients were randomly assigned with an Internet-based randomization Web site. Randomization was performed within 72 hours of the commencement of chemotherapy.""</p><p>The baseline mean Hb concentrations of the control and experimental groups were not significantly different (96.3 g/L vs. 96.5 g/L, p = 0.956).</p>","Some concerns","<p>No information provided with regards to deviations from intervention. There was a large proportion of non-compliance with intervention in both groups, although no significant difference between compliance between groups was calculated.</p><p>""Given the nature of the intervention and the need for health-care professionals to be aware of the patient’s laboratory results, it was not possible for this study to be double blind. Furthermore, patients on the hematology ward tend to keep charts of their Hb and PLT values, and knowledge of their “blood counts” may be an important part of their treatment. Therefore, it was considered unethical to keep the patients unaware of their treatment assignment.”&nbsp;</p><p>“Outcome assessors were blinded, a member of the study group would assess clinical records to check if any bleeding episodes were missed. Bleeding reviews at weekend performed on Monday through review of patient's chart (not all bleeding episodes may have been recorded).&nbsp;The study personnel performing the clinical assessment of bleeding, however, were blinded to the patient’s treatment allocation.""</p><p>“To minimize possible reporting bias, all instances of clinically relevant bleeding documented on the daily assessment report were reviewed independently by an adjudication committee who were blinded to the patients’ treatment assignments and Hb levels.""</p>","Low risk","<p>""The proportion of days of assessment with completed forms was 0.99 in both the control and the experimental groups, respectively.""</p>","Low risk","<p>Bleeding assessments made were comparable to the World Health Organization (WHO) scoring system. Method of measuring severe bleeds provided by the authors would be assumed to be completed using similar methods</p><p>“Outcome assessors were blinded, a member of the study group would assess clinical records to check if any bleeding episodes were missed. Bleeding reviews at weekend performed on Monday through review of patient's chart (not all bleeding episodes may have been recorded).&nbsp;The study personnel performing the clinical assessment of bleeding, however, were blinded to the patient’s treatment allocation.""</p><p>“To minimize possible reporting bias, all instances of clinically relevant bleeding documented on the daily assessment report were reviewed independently by an adjudication committee who were blinded to the patients’ treatment assignments and Hb levels.""</p>","Low risk","<p>No trial protocol was available and data provided by authors.&nbsp;</p><p>Publication reported all bleeding and clinically significant bleeding, did not report all grades of bleeding separately. Given the rare frequency of severe events provided by the authors and the greater practical significant of clinically significant bleeding, it is unlikely that there was bias in outcome selection</p>","Some concerns","<p>The outcome is judged to have some concern&nbsp;for bias in domain 2</p>","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011305.pub3/full","10.1002/14651858.CD011305.pub3","10::overall","CD011305_pub3_data","direction_only",FALSE,FALSE,FALSE,0.00272529222196641,-0.00211768333568689,-1.01646249473177,1.02191307917571,-0.0270250551117067,0.0227896884403329,TRUE,FALSE
